risk-adjusted safety analysis of pacritinib for patients with mf
Published 2 years ago • 249 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
0:54
study design for persist-2 and other upcoming trials of pacritinib
-
4:12
pacritinib for patients with mf across the cytopenic spectrum
-
0:56
pacifica: pacritinib versus physician’s choice in myelofibrosis
-
2:18
results of persist-1 & persist-2 studies of pacritinib vs best alternative therapy in myelofibrosis
-
4:22
accelerated-phase mpns: pathophysiology, treatment approaches and ongoing clinical trials
-
56:23
aav capsid discovery and design – novel sequencing approaches
-
59:02
[tctap 2022 - case session] 2. complex pci
-
3:37
biorepository unit video june 2023
-
2:04
design and results of persist-1 trial of pacritinib for myelofibrosis
-
3:46
results of the phase iii persist-1 trial of pacritinib for myelofibrosis
-
2:03
preliminary results of a phase ii study of fedratinib in patients with mds/mpn and cnl
-
3:56
results of the phase ii titan study of caplacizumab in patients with attp
-
4:48
an insight into the management of cytopenias in mf
-
2:57
preliminary data from the manifest study: pelabresib in combination with ruxolitinib in mf
-
1:49
phase ii trial-in-progress of itacitinib in patients with myelofibrosis
-
1:30
insights into the manifest-2 study
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
1:49
results from manifest phase ii study of pelabresib for anemia associated with myelofibrosis
-
3:29
current approaches and new approvals in mf and pv
-
3:54
cytopenic mf: new approaches
-
3:56
an update on manifest: pelabresib monotherapy or as add-on to ruxolitinib in myelofibrosis
-
2:40
the future treatment and management of mpns